Fecal calprotectin in systemic sclerosis and review of the literature

Autoimmunity Reviews

Volumn 14, Issue 6, 2015, Pages 547-554

  Marie, I ^a   Leroi, A M ^a   Menard, J F ^b   Levesque, H ^a   Quillard, M ^b   Ducrotte, P ^a  

^a UNIVERSITÉ DE ROUEN   (France)

^b ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

Fecal calprotectin; Gastrointestinal involvement; Inflammation; Predictive value; Small intestinal bacterial overgrowth; Systemic sclerosis

Indexed keywords

ANTIINFECTIVE AGENT; AZATHIOPRINE; CALGRANULIN; GLUCOSE; METHOTREXATE; MYCOPHENOLATE MOFETIL;

ADULT; AGED; ANTIBIOTIC THERAPY; BREATH ANALYSIS; DELAYED GASTRIC EMPTYING; ERADICATION THERAPY; ESOPHAGEAL MOTOR DISORDER; ESOPHAGUS; ESOPHAGUS MANOMETRY; FECES; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TRACT; GLOBAL SYMPTOM SCORE; GLUCOSE BREATH TEST; HUMAN; HYDROGEN AND METHANE BREATH TEST; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; QUESTIONNAIRE; REVIEW; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SMALL INTESTINAL BACTERIAL OVERGROWTH; SYSTEMIC SCLEROSIS; VERY ELDERLY; CHEMISTRY; COMPLICATION; SCLERODERMA, SYSTEMIC;

BREATH TESTS; FECES; HUMANS; LEUKOCYTE L1 ANTIGEN COMPLEX; QUESTIONNAIRES; SCLERODERMA, SYSTEMIC; SURVEYS AND QUESTIONNAIRES;

EID: 84933673366     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2015.01.018     Document Type: Review

References (66)

1. Bernal-Bello D., García de Tena J., Simeón-Aznar C., Fonollosa-Pla V. Systemic sclerosis, breast cancer and calcium channel blockers: a new player on the scene?. Autoimmun Rev 2014, 13:880-881.
2. Chora I., Guiducci S., Manetti M., Romano E., Mazzotta C., Bellando-Randone S., et al. Vascular biomarkers and correlation with peripheral vasculopathy in systemic sclerosis. Autoimmun Rev 2015, 14:314-322.
3. Cipriani P., Carubbi F., Liakouli V., Marrelli A., Perricone C., Perricone R., et al. Stem cells in autoimmune diseases: implications for pathogenesis and future trends in therapy. Autoimmun Rev 2013, 12:709-716.
4. Colaci M., Giuggioli D., Sebastiani M., Manfredi A., Vacchi C., Spagnolo P., et al. Lung cancer in scleroderma: results from an Italian rheumatologic center and review of the literature. Autoimmun Rev 2013, 12:374-379.
5. Colaci M., Giuggioli D., Vacchi C., Lumetti F., Iachetta F., Marcheselli L., et al. Breast cancer in systemic sclerosis: results of a cross-linkage of an Italian Rheumatologic Center and a population-based Cancer Registry and review of the literature. Autoimmun Rev 2014, 13:132-137.
6. Elhai M., Avouac J., Kahan A., Allanore Y. Systemic sclerosis at the crossroad of polyautoimmunity. Autoimmun Rev 2013, 12:1052-1057.
7. Ferri C., Sebastiani M., Lo Monaco A., Iudici M., Giuggioli D., Furini F., et al. Systemic sclerosis evolution of disease pathomorphosis and survival. Our experience on Italian patients' population and review of the literature. Autoimmun Rev 2014, 13:1026-1034.
8. Giuggioli D., Manfredi A., Colaci M., Manzini C.U., Antonelli A., Ferri C. Systemic sclerosis and cryoglobulinemia: our experience with overlapping syndrome of scleroderma and severe cryoglobulinemic vasculitis and review of the literature. Autoimmun Rev 2013, 12:1058-1063.
9. Jimenez S.A., Piera-Velazquez S. Potential role of human-specific genes, human-specific microRNAs and human-specific non-coding regulatory RNAs in the pathogenesis of systemic sclerosis and Sjögren's syndrome. Autoimmun Rev 2013, 12:1046-1051.
10. Lanteri A., Sobanski V., Langlois C., Lefèvre G., Hauspie C., Sanges S., et al. Serum free light chains of immunoglobulins as biomarkers for systemic sclerosis characteristics, activity and severity. Autoimmun Rev 2014, 13:974-980.
11. Mehra S., Walker J., Patterson K., Fritzler M.J. Autoantibodies in systemic sclerosis. Autoimmun Rev 2013, 12:340-354.
12. Rossi D., Russo A., Manna E., Binello G., Baldovino S., Sciascia S., et al. The role of nail-videocapillaroscopy in early diagnosis of scleroderma. Autoimmun Rev 2013, 12:821-825.
13. Silva I., Almeida J., Vasconcelos C. A PRISMA-driven systematic review for predictive risk factors of digital ulcers in systemic sclerosis patients. Autoimmun Rev 2015, 14:140-152.
14. Valentini G. Undifferentiated connective tissue disease at risk for systemic sclerosis (SSc) (so far referred to as very early/early SSc or pre-SSc). Autoimmun Rev 2015, 14:210-213.
15. Villalta D., Imbastaro T., Di Giovanni S., Lauriti C., Gabini M., Turi M.C., et al. Diagnostic accuracy and predictive value of extended autoantibody profile in systemic sclerosis. Autoimmun Rev 2012, 12:114-120.
16. Forbes A., Marie I. Gastrointestinal complications: the most frequent internal complications of systemic sclerosis. Rheumatology (Oxford) 2009, 48:iii36-iii39.
17. Marie I., Antonietti M., Houivet E., Hachulla E., Maunoury V., Bienvenu B., et al. Gastrointestinal mucosal abnormalities using videocapsule endoscopy in systemic sclerosis. Aliment Pharmacol Ther 2014, 40:189-199.
18. Marie I., Ducrotte P., Antonietti M., Herve S., Levesque H. Watermelon stomach in systemic sclerosis: its incidence and management. Aliment Pharmacol Ther 2008, 28:412-421.
19. Marie I., Dominique S., Levesque H., Ducrotté P., Denis P., Hellot M.F., et al. Esophageal involvement and pulmonary manifestations in systemic sclerosis. Arthritis Rheum 2001, 45:346-354.
20. Marie I., Ducrotté P., Denis P., Hellot M.F., Levesque H. Oesophageal mucosal involvement in patients with systemic sclerosis receiving proton pump inhibitor therapy. Aliment Pharmacol Ther 2006, 24:1593-1601.
21. Marie I., Ducrotté P., Denis P., Hellot M.F., Levesque H. Outcome of small bowel motor impairment in systemic sclerosis: a prospective manometric 5-year follow-up. Rheumatology (Oxford) 2007, 46:150-153.
22. Marie I., Gehanno J.F., Bubenheim M., Duval-Modeste A.B., Joly P., Dominique S., et al. Prospective study to evaluate the association between systemic sclerosis and occupational exposure and review of the literature. Autoimmun Rev 2014, 13:151-156.
23. Marie I., Gourcerol G., Leroi A.M., Ménard J.F., Levesque H., Ducrotté P. Delayed gastric emptying determined using the 13C-octanoic acid breath test in patients with systemic sclerosis. Arthritis Rheum 2012, 64:2346-2355.
24. Marie I., Levesque H., Ducrotté P., Denis P., Hellot M.F., Benichou J. Gastric involvement in systemic sclerosis: a prospective study. Am J Gastroenterol 2001, 41:1874-1883.
25. Marie I., Levesque H., Ducrotté P., Denis P., Benichou J., Hellot M.F., et al. Manometry of the upper intestinal tract in patients with systemic sclerosis: a prospective study. Arthritis Rheum 1998, 96:77-83.
26. Poirier T.J., Rankin G.B. Gastrointestinal manifestations of progressive systemic scleroderma based on a review of 364 cases. Am J Gastroenterol 1972, 58:30-44.
27. Marie I., Ducrotté P., Denis P., Menard J.F., Levesque H. Small intestinal bacterial overgrowth in systemic sclerosis. Rheumatology (Oxford) 2009, 48:1314-1319.
28. Atzeni F., Defendenti C., Ditto M.C., Batticciotto A., Ventura D., Antivalle M., et al. Rheumatic manifestations in inflammatory bowel disease. Autoimmun Rev 2014, 13:20-23.
29. Bashi T., Bizzaro G., Ben-Ami Shor D., Blank M., Shoenfeld Y. The mechanisms behind helminth's immunomodulation in autoimmunity. Autoimmun Rev 2015, 14:98-104.
30. Ben-Horin S., Kopylov U., Chowers Y. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev 2014, 13:24-30.
31. Bonneau J., Dumestre-Perard C., Rinaudo-Gaujous M., Genin C., Sparrow M., Roblin X., et al. Systematic review: new serological markers (anti-glycan, anti-GP2, anti-GM-CSF Ab) in the prediction of IBD patient outcomes. Autoimmun Rev 2015, 14:231-245.
32. Cassinotti A., Sarzi-Puttini P., Fichera M., Shoenfeld Y., de Franchis R., Ardizzone S. Immunity, autoimmunity and inflammatory bowel disease. Autoimmun Rev 2014, 13:1-2.
33. Conrad K., Roggenbuck D., Laass M.W. Diagnosis and classification of ulcerative colitis. Autoimmun Rev 2014, 13:463-466.
34. Fiorino G., Danese S., Pariente B., Allez M. Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-α agents. Autoimmun Rev 2014, 13:15-19.
35. Fiorino G., Girolomoni G., Lapadula G., Orlando A., Danese S., Olivieri I., SIR, SIDeMaST, IG-IBD The use of biosimilars in immune-mediated disease: a joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper. Autoimmun Rev 2014, 13:751-755.
36. Geremia A., Biancheri P., Allan P., Corazza G.R., Di Sabatino A. Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev 2014, 13:3-10.
37. Laass M.W., Roggenbuck D., Conrad K. Diagnosis and classification of Crohn's disease. Autoimmun Rev 2014, 13:467-471.
38. Lin J.F., Chen J.M., Zuo J.H., Yu A., Xiao Z.J., Deng F.H., et al. Meta-analysis: fecal calprotectin for assessment of inflammatory bowel disease activity. Inflamm Bowel Dis 2014, 20:1407-1415.
39. Lin C.H., Kadakia S., Frieri M. New insights into an autoimmune mechanism, pharmacological treatment and relationship between multiple sclerosis and inflammatory bowel disease. Autoimmun Rev 2014, 13:114-116.
40. Ma H.D., Wang Y.H., Chang C., Gershwin M.E., Lian Z.X. The intestinal microbiota and microenvironment in liver. Autoimmun Rev 2015, 14:183-191.
41. Meuwis M.A., Vernier-Massouille G., Grimaud J.C., Bouhnik Y., Laharie D., Piver E., et al. GETAID (Groupe d'Étude Thérapeutique Des Affections Inflammatoires Digestives). Serum calprotectin as a biomarker for Crohn's disease. J Crohns Colitis 2013, 7:e678-e683.
42. Monteleone G., Caruso R., Pallone F. Targets for new immunomodulation strategies in inflammatory bowel disease. Autoimmun Rev 2014, 13:11-14.
43. Olivieri I., Cantini F., Castiglione F., Felice C., Gionchetti P., Orlando A., et al. Italian Expert Panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease. Autoimmun Rev 2014, 13:822-830.
44. Rogosnitzky M., Danks R., Holt D. Intravenous immunoglobulin for the treatment of Crohn's disease. Autoimmun Rev 2012, 12:275-280.
45. Andréasson K., Saxne T., Scheja A., Bartosik I., Mandl T., Hesselstrand R. Faecal levels of calprotectin in systemic sclerosis are stable over time and are higher compared to primary Sjögren's syndrome and rheumatoid arthritis. Arthritis Res Ther 2014, 16:R46.
46. Andréasson K., Scheja A., Saxne T., Ohlsson B., Hesselstrand R. Faecal calprotectin: a biomarker of gastrointestinal disease in systemic sclerosis. J Intern Med 2011, 270:50-57.
47. van den Hoogen F., Khanna D., Fransen J., Johnson S.R., Baron M., Tyndall A., Matucci-Cerinic M., Naden R.P., Medsger T.A., Carreira P.E., Riemekasten G., Clements P.J., Denton C.P., Distler O., Allanore Y., Furst D.E., Gabrielli A., Mayes M.D., van Laar J.M., Seibold J.R., Czirjak L., Steen V.D., Inanc M., Kowal-Bielecka O., Müller-Ladner U., Valentini G., Veale D.J., Vonk M.C., Walker U.A., Chung L., Collier D.H., Csuka M.E., Fessler B.J., Guiducci S., Herrick A., Hsu V.M., Jimenez S., Kahaleh B., Merkel P.A., Sierakowski S., Silver R.M., Simms R.W., Varga J., Pope J.E. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2013, 65:2737-2747.
48. Leroy E.C., Black C., Fleischmajer R., Jablonska S., Krieg T., Medsger T.A., et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988, 15:202-205.
49. Louis E., Mary J.Y., Vernier-Massouille G., Grimaud J.C., Bouhnik Y., Laharie D., Groupe D'etudes Thérapeutiques Des Affections Inflammatoires Digestives, et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012, 142:63-70.
50. Gisbert J.P., McNicholl A.G. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig Liver Dis 2009, 41:56-66.
51. Johnson M.W., Maestranzi S., Duffy A.M., Dewar D.H., Forbes A., Bjarnason I., et al. Faecal calprotectin: a noninvasive diagnostic tool and marker of severity in pouchitis. Eur J Gastroenterol Hepatol 2008, 20:174-179.
52. Montalto M., Gallo A., Santoro L., D'Onofrio F., Landolfi R., Gasbarrini A. Role of fecal calprotectin in gastrointestinal disorders. Eur Rev Med Pharmacol Sci 2013, 17:1569-1582.
53. Moum B., Jahnsen J., Bernklev T. Fecal calprotectin variability in Crohn's disease. Inflamm Bowel Dis 2010, 16:1091-1092.
54. Gebhardt C., Németh J., Angel P., Hess J. S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol 2006, 72:1622-1631.
55. Vermeire S., Van Assche G., Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys?. Gut 2006, 55:426-431.
56. Foell D., Wittkowski H., Vogl T., Roth J. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol 2007, 81:28-37.
57. Limburg P.J., Devens M.E., Harrington J.J., Diehl N.N., Mahoney D.W., Ahlquist D.A. Prospective evaluation of fecal calprotectin as a screening biomarker for colorectal neoplasia. Am J Gastroenterol 2003, 98:2299-2305.
58. Bruzzese E., Callegari M.L., Raia V., Viscovo S., Scotto R., Ferrari S., et al. Disrupted intestinal microbiota and intestinal inflammation in children with cystic fibrosis and its restoration with Lactobacillus GG: a randomised clinical trial. PLoS One 2014, 9:e87796.
59. Chen C.C., Huang J.L., Chang C.J., Kong M.S. Fecal calprotectin as a correlative marker in clinical severity of infectious diarrhea and usefulness in evaluating bacterial or viral pathogens in children. J Pediatr Gastroenterol Nutr 2012, 55:541-547.
60. Larsson G., Shenoy K.T., Ramasubramanian R., Thayumanavan L., Balakumaran L.K., Bjune G.A., et al. Faecal calprotectin levels differentiate intestinal from pulmonary tuberculosis: an observational study from Southern India. United European Gastroenterol J 2014, 2:397-405.
61. Nielsen H.L., Engberg J., Ejlertsen T., Nielsen H. Evaluation of fecal calprotectin in Campylobacter concisus and Campylobacter jejuni/coli gastroenteritis. Scand J Gastroenterol 2013, 48:633-635.
62. Ibba-Manneschi L., Del Rosso A., Pacini S., Tani A., Bechi P., Matucci Cerinic M. Ultrastructural study of the muscle coat of the gastric wall in a case of systemic sclerosis. Ann Rheum Dis 2002, 61:754-756.
63. Manetti M., Neumann E., Müller A., Schmeiser T., Saar P., Milia A.F., et al. Endothelial/lymphocyte activation leads to prominent CD4+ T cell infiltration in the gastric mucosa of patients with systemic sclerosis. Arthritis Rheum 2008, 58:2866-2873.
64. Roberts C.G., Hummers L.K., Ravich W.J., Wigley F.M., Hutchins G.M. A case-control study of the pathology of oesophageal disease in systemic sclerosis (scleroderma). Gut 2006, 55:1697-1703.
65. Matzkies F.G., Targan S.R., Berel D., Landers C.J., Reveille J.D., McGovern D.P., et al. Markers of intestinal inflammation in patients with ankylosing spondylitis: a pilot study. Arthritis Res Ther 2012, 14:R261.
66. Guardiola J., Lobatón T., Rodríguez-Alonso L., Ruiz-Cerulla A., Arajol C., Loayza C., et al. Fecal level of calprotectin identifies histologic inflammation in patients with ulcerative colitis in clinical and endoscopic remission. Clin Gastroenterol Hepatol 2014, S1542-3565(14):925-926.